US3608079A - Thiouracil-carboxylic acids for treatment of viruses - Google Patents

Thiouracil-carboxylic acids for treatment of viruses Download PDF

Info

Publication number
US3608079A
US3608079A US722183A US3608079DA US3608079A US 3608079 A US3608079 A US 3608079A US 722183 A US722183 A US 722183A US 3608079D A US3608079D A US 3608079DA US 3608079 A US3608079 A US 3608079A
Authority
US
United States
Prior art keywords
carboxylic acid
thiouracil
component
uracil
dose
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
US722183A
Inventor
Hermann Moor
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
CHEMOFARMA AG
Original Assignee
CHEMOFARMA AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by CHEMOFARMA AG filed Critical CHEMOFARMA AG
Application granted granted Critical
Publication of US3608079A publication Critical patent/US3608079A/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients

Definitions

  • compositions comprising 2- thioui'acil-4-carboxylic acid and uracil-4-carboxylic acid and their nontoxic salts or lower alkyl esters. These compositions are effective in providing a nonspecific activity against virus warts, Molluscum contagiosum, Condylomata acuminata, Herpes simplex, and Herpes zoster.
  • THIOURACIL-CARBOXYLIC ACIDS FOR TREATMENT OF VIRUSES SUMMARY OF THE INVENTION The present invention is based upon the discovery that a useful chemotherapeutic effect in human beings can be obtained by the administration of a thiouracil-carboxylic acid, preferably 2-thiouracil-4-carboxylic acid which is the compound of formula
  • pharmaceutical or nutritional compositions for human use comprising as active ingredient a thiouracil-carboxylic acid, or a nontoxic salt or alkyl ester of a thiouracilcarboxylic acid, together with one or more carriers or excipients as herein defined.
  • the thiocuracil-carboxylic acid used in the compositions according to the invention is preferably a 2'thiouracil-carboxylic acid.
  • 2-Thiouracil-4-carboxylic acid and salts and alkyl esters thereof are particularly preferred active ingredients.
  • non-toxic as used herein in relation to the salts of thiouracil-carboxylic acids we mean such salts the cationic portions of which are physiologically compatible in the dosages used.
  • Preferred salts include alkali metal salts such as the sodium and potassium salts, and ammonium and quaternary ammonium salts such as for example the choline salt.
  • Preferred alkyl esters are esters in which the alkyl group is a lower alkyl group containing from one to five carbon atoms, especially a methyl or ethyl group.
  • the expression carriers or excipients as used herein means any solid or liquid carrier or excipient suitable for the formulation of pharmaceutical and nutritional compositions, but does not include water or solvents alone which together with the other component or components of the composition in the concentrations in which they are present give rise to mere known solutions.
  • compositions according to the invention may be presented in a form suitable for oral, rectal or parenteral administration.
  • compositions for oral administration may be solid or liquid and may take the form of capsules, tablets, coated tablets, cachets, granules, powders, syrups, suspensions, etc., such compositions including carriers or excipients conveniently used in the pharmaceutical art.
  • Suitable tabletting excipients include lactose, potato and maize starches, talc, gelatine, and stearic and silicic acids, magnesium stearate and polyvinylpyrrolidone.
  • the carrier or excipient may be a sterile, parenterally acceptable liquid, e.g. pyrogen-free water or an aqueous solution of polyvinylpyrrolidone, or a parenterally acceptable oil, e.g. arachis oil, contained in ampuls.
  • a parenterally acceptable liquid e.g. pyrogen-free water or an aqueous solution of polyvinylpyrrolidone
  • a parenterally acceptable oil e.g. arachis oil
  • the carrier may comprise a suppository base, e.g., cocoa butter or other glyceride.
  • the carrier may be provided by a foodstuff such as for example milk powder.
  • compositions may be formulated as dosage units, each unit being adapted to supply a fixed dose of active ingredient.
  • Tablets, coated tablets, capsules, pills, cachets, ampuls and suppositories are examples of preferred dosage unit forms according to the invention, which con.- veniently contain from 0.1 to 100 mg., preferably 0.5 to mg., of active ingredient.
  • compositions according to the invention as hereinbefore defined in general assists in providing a nonspecific activity against virus warts and diseases such as for example Molluscum contagiosum, condylomata acuminata, Herpes simplex and Herpes zoster. it has been found that an improved eflect is generally obtained if the thiouracilcarboxylic acid component is administered together with a uracil-carboxylic acid or a nontoxic salt or alkyl ester thereof.
  • the uracil-carboxylic acid is preferably uracil-4-caryoxylic acid but may also for example be provided by uracil-S-carboxylic acid, uracil-4,5- dicarboxylic acid and nontoxic salts and alkyl esters of such acids.
  • preferred compositions according to the invention contain a uracil-carboxylic acid, the particularly preferred ratio by weight of the thiouracilcarboxylic acid (or nontoxic salt or alkyl ester thereof) to uracil-carboxylic acid (or nontoxic salt or alkyl ester thereof) being from 1:1 to l:50, by weight.
  • thiouracil-carboxylic acid component is administered together with methionine or a biological equivalent thereof such as for example hydroxymethionine or methoxy-methionine.
  • methionine or other biological methylating agent that is an agent capable of effecting the introduction of methyl groups under biological conditions.
  • the biological methylating agents may for example be physiological methyl donors and methionine, hydroxy-methionine and methoxymethionine are of course well-known methyl donors. Other such donors include choline and S-methyl-tetrahydrofolic acid.
  • methyl donors possess a comparatively labile methyl group. Such a methyl group will generally be attached to a sulfur atom (as in methionine) or a nitrogen atom (as in choline).
  • compositions according to the invention contain methionine or other biological methylating agent, the ratio by weight of the thiouracil carboxylic acid (or nontoxic salt or alkyl ester thereof) to biological methylating agent being from 1:10 to l: 200, advantageously about 1: 100, by weight.
  • a pharmaceutical or nutritional composition which comprises a thiouracilcarboxylic acid or a nontoxic salt or alkyl ester of a thiouracil-carboxylic acid, together with methionine (or other biologicalmethylating agent and/or a uracil-carboylic acid (or a nontoxic salt or alkyl ester thereof).
  • compositions according to the invention in general assists in providing a nonspecific activity against virus warts and diseases such as for example Molluscum contagiosum, Condylomata acuminata, Herpes simplex and Herpes zoster.
  • Compositions containing for example 2-thiouracil-4- carboxylic acid, uracil-4-carboxylic acid and methionine e.g. in a ratio by weight of about 12:10: 100, stimulate the production of active lymphocytes.
  • compositions according to the invention containing for example 2-thiouracil-4-carboxylic acid, uracil-4-carboxylic acid and methionine in a ratio by weight of about 1:10:100 have been found in these circumstances to promote a new formation of lymphocytes and thus to resuscitate the defensive mechanism of the body.
  • composition according to the invention containing 2- thiouracil-4-carboxylic acid, uracil-4-carboxylic acid and methioine in a ratio by weight of about 1:10:100 is useful in the treatment of virus warts and diseases such as for example Molluscum contagiosum, Condylomata acuminata, Herpes simplex and Herpes zoster. It also leads to an increase in the erythrocytes in the blood.
  • thiouracil-carboxylic acids and nontoxic salts and alkyl esters thereof may be antimetabolites of uracil which are taken up by virus (pl.) and which stunt or inhibit the growth thereof.
  • Thiouracil-carboxylic acids are substances having generally low toxicity.
  • 2-thiouracil- 4-carboxylic acid has been administered orally to rats at a dosage of 0.5 g./kg. of body weight for over 90 days without any toxic effects.
  • thiouracil-4-carboxylic acid has no influence on the activity of the thyroid gland and so it efiects neither the oxygen consumption of the body nor the basal metabolic rate.
  • the thiouracil-carboxylic acid (or nontoxic salt or alkyl ester thereof) is preferably administered at a dose of about 1 to 500 mg. advantageously to 50 mg., per day.
  • a uracil-carboxylic acid or nontoxic salt or alkyl ester thereof
  • the latter is preferably administered at a dosage of about 50 mg. to l l g., advantageously 100 to 500 mg., per day.
  • methionine or a biological equivalent thereof
  • the latter is preferably administered at a dosage of about 1 to 10 g., advantageously 3 to 5 g., per day.
  • the recommended dose is 4 or 5 capsules per day.
  • EXAMPLE 2 Ampuls are prepared each of which contains the following: 30 mg. of the choline salt of Z-thiouracil-4carboxylic acid 200 mg. uracil-4-carboxylic acid, choline salt 250 mg. dl-methionine The ingredients are filled into dry ampuls. In use, one gives 15 ml. sterile, physiological salt solution in the ampul and immediately after dissolution of the active ingredients, the ampul solution is injected (preferably subcutaneoysly).
  • EXAMPLE 3 Dietetic preparation mg. 2-thiouracil-4-carboxylic acid are homogeneously mixed in 100 g. milk powder. This mild powder is if desired made aromatic. In use, 20 g. of this powder may be dissolved in a cup of hot water and given one to two times daily.
  • a pharmaceutical composition which comprises as active ingredients:
  • uracil-4-carboxylic acid or a nontoxic salt or lower alkyl ester thereof;
  • component (a) to component (b) wherein the ratio by weight of component (a) to component (b) is about 1:10 and the weight of (a) per dosage unit is from 0.1 mg. to 100 mg.
  • a method of providing a nonspecific activity against virus warts, Molluscum contagiosum, Condylomata acuminata, Herpes simplex, and Herpes zoster in humans which comprises administering thereto a pharmaceutical composition which comprises as active ingredients:
  • component (a) in an amount sufficient to provide a dose of about I to 500 mg. per day of component (a), and a dose of about 50 mg. to l gm. per day of component (b), wherein the ratio by weight of component (a) to component (b) is from 1:1 to l: 50.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Pharmaceutical compositions comprising 2-thiouracil-4-carboxylic acid and uracil-4-carboxylic acid and their nontoxic salts or lower alkyl esters. These compositions are effective in providing a nonspecific activity against virus warts, Molluscum contagiosum, Condylomata acuminata, Herpes simplex, and Herpes zoster.

Description

United States Patent 5 Claims, No Drawings Inventor Hermann Moor Binningen, Switzerland Appl. No. 722,183 Filed Apr. 18, 1968 Patented Sept. 21, 1971 Assignee Chemoforma A. G.
Basel-Landschalt, Switzerland Priority Apr. 19, 1967 Great Britain 18,102/67 THIOURAClL-CARBOXYLIC ACIDS FOR TREATMENT OF VIRUSES Carrara et al. Chem. Abst. Vol. 53-1959 page 7432d Primary ExaminerSam Rosen Atl0meyBacon & Thomas ABSTRACT: Pharmaceutical compositions comprising 2- thioui'acil-4-carboxylic acid and uracil-4-carboxylic acid and their nontoxic salts or lower alkyl esters. These compositions are effective in providing a nonspecific activity against virus warts, Molluscum contagiosum, Condylomata acuminata, Herpes simplex, and Herpes zoster.
THIOURACIL-CARBOXYLIC ACIDS FOR TREATMENT OF VIRUSES SUMMARY OF THE INVENTION The present invention is based upon the discovery that a useful chemotherapeutic effect in human beings can be obtained by the administration of a thiouracil-carboxylic acid, preferably 2-thiouracil-4-carboxylic acid which is the compound of formula According to one feature of the present invention, there are provided pharmaceutical or nutritional compositions for human use comprising as active ingredient a thiouracil-carboxylic acid, or a nontoxic salt or alkyl ester of a thiouracilcarboxylic acid, together with one or more carriers or excipients as herein defined.
The thiocuracil-carboxylic acid used in the compositions according to the invention is preferably a 2'thiouracil-carboxylic acid. 2-Thiouracil-4-carboxylic acid and salts and alkyl esters thereof are particularly preferred active ingredients.
By the term non-toxic as used herein in relation to the salts of thiouracil-carboxylic acids we mean such salts the cationic portions of which are physiologically compatible in the dosages used. Preferred salts include alkali metal salts such as the sodium and potassium salts, and ammonium and quaternary ammonium salts such as for example the choline salt. Preferred alkyl esters are esters in which the alkyl group is a lower alkyl group containing from one to five carbon atoms, especially a methyl or ethyl group.
The expression carriers or excipients" as used herein means any solid or liquid carrier or excipient suitable for the formulation of pharmaceutical and nutritional compositions, but does not include water or solvents alone which together with the other component or components of the composition in the concentrations in which they are present give rise to mere known solutions.
The pharmaceutical compositions according to the invention may be presented in a form suitable for oral, rectal or parenteral administration. Thus, for example, compositions for oral administration may be solid or liquid and may take the form of capsules, tablets, coated tablets, cachets, granules, powders, syrups, suspensions, etc., such compositions including carriers or excipients conveniently used in the pharmaceutical art. Suitable tabletting excipients include lactose, potato and maize starches, talc, gelatine, and stearic and silicic acids, magnesium stearate and polyvinylpyrrolidone.
For parenteral administration, the carrier or excipient may be a sterile, parenterally acceptable liquid, e.g. pyrogen-free water or an aqueous solution of polyvinylpyrrolidone, or a parenterally acceptable oil, e.g. arachis oil, contained in ampuls.
In compositions for rectal administration, the carrier may comprise a suppository base, e.g., cocoa butter or other glyceride.
ln nutritional compositions according to the invention, the carrier may be provided by a foodstuff such as for example milk powder.
Advantageously, the compositions may be formulated as dosage units, each unit being adapted to supply a fixed dose of active ingredient. Tablets, coated tablets, capsules, pills, cachets, ampuls and suppositories are examples of preferred dosage unit forms according to the invention, which con.- veniently contain from 0.1 to 100 mg., preferably 0.5 to mg., of active ingredient.
The administration of pharmaceutical and nutritional compositions according to the invention as hereinbefore defined in general assists in providing a nonspecific activity against virus warts and diseases such as for example Molluscum contagiosum, condylomata acuminata, Herpes simplex and Herpes zoster. it has been found that an improved eflect is generally obtained if the thiouracilcarboxylic acid component is administered together with a uracil-carboxylic acid or a nontoxic salt or alkyl ester thereof. The uracil-carboxylic acid is preferably uracil-4-caryoxylic acid but may also for example be provided by uracil-S-carboxylic acid, uracil-4,5- dicarboxylic acid and nontoxic salts and alkyl esters of such acids. Thus preferred compositions according to the invention contain a uracil-carboxylic acid, the particularly preferred ratio by weight of the thiouracilcarboxylic acid (or nontoxic salt or alkyl ester thereof) to uracil-carboxylic acid (or nontoxic salt or alkyl ester thereof) being from 1:1 to l:50, by weight.
It has further been found that an improved effect is generally obtained if the thiouracil-carboxylic acid component is administered together with methionine or a biological equivalent thereof such as for example hydroxymethionine or methoxy-methionine. It is thus advantageous to include in the compositions according to the invention, a proportion of methionine or other biological methylating agent, that is an agent capable of effecting the introduction of methyl groups under biological conditions. The biological methylating agents may for example be physiological methyl donors and methionine, hydroxy-methionine and methoxymethionine are of course well-known methyl donors. Other such donors include choline and S-methyl-tetrahydrofolic acid. In general, methyl donors possess a comparatively labile methyl group. Such a methyl group will generally be attached to a sulfur atom (as in methionine) or a nitrogen atom (as in choline).
Preferred compositions according to the invention contain methionine or other biological methylating agent, the ratio by weight of the thiouracil carboxylic acid (or nontoxic salt or alkyl ester thereof) to biological methylating agent being from 1:10 to l: 200, advantageously about 1: 100, by weight.
According to a further feature of the present invention, there is thus provided a pharmaceutical or nutritional composition which comprises a thiouracilcarboxylic acid or a nontoxic salt or alkyl ester of a thiouracil-carboxylic acid, together with methionine (or other biologicalmethylating agent and/or a uracil-carboylic acid (or a nontoxic salt or alkyl ester thereof).
As stated above, the administration of compositions according to the invention in general assists in providing a nonspecific activity against virus warts and diseases such as for example Molluscum contagiosum, Condylomata acuminata, Herpes simplex and Herpes zoster. Compositions containing for example 2-thiouracil-4- carboxylic acid, uracil-4-carboxylic acid and methionine e.g. in a ratio by weight of about 12:10: 100, stimulate the production of active lymphocytes.
Where the tissue of the human body is forced by irritation to an over-production of lymphocytes for a long period of time, the lymphatic ganglions may degenerate with a breakdown in the defensive mechanism of the body. Compositions according to the invention containing for example 2-thiouracil-4-carboxylic acid, uracil-4-carboxylic acid and methionine in a ratio by weight of about 1:10:100 have been found in these circumstances to promote a new formation of lymphocytes and thus to resuscitate the defensive mechanism of the body.
It has for example been demonstrated that a composition according to the invention containing 2- thiouracil-4-carboxylic acid, uracil-4-carboxylic acid and methioine in a ratio by weight of about 1:10:100 is useful in the treatment of virus warts and diseases such as for example Molluscum contagiosum, Condylomata acuminata, Herpes simplex and Herpes zoster. It also leads to an increase in the erythrocytes in the blood.
Thus thiouracil-carboxylic acids and nontoxic salts and alkyl esters thereof may be antimetabolites of uracil which are taken up by virus (pl.) and which stunt or inhibit the growth thereof.
Thiouracil-carboxylic acids are substances having generally low toxicity. Thus for example 2-thiouracil- 4-carboxylic acid has been administered orally to rats at a dosage of 0.5 g./kg. of body weight for over 90 days without any toxic effects. Further it has been shown that thiouracil-4-carboxylic acid has no influence on the activity of the thyroid gland and so it efiects neither the oxygen consumption of the body nor the basal metabolic rate.
The thiouracil-carboxylic acid (or nontoxic salt or alkyl ester thereof) is preferably administered at a dose of about 1 to 500 mg. advantageously to 50 mg., per day. When administered together with a uracil-carboxylic acid (or nontoxic salt or alkyl ester thereof), the latter is preferably administered at a dosage of about 50 mg. to l l g., advantageously 100 to 500 mg., per day. When administered together with methionine (or a biological equivalent thereof), the latter is preferably administered at a dosage of about 1 to 10 g., advantageously 3 to 5 g., per day.
The following examples illustrate the invention:
EXAMPLE 1 Gelatin capsules are prepared each of which contains the following ingredients:
Methionine 250 mg. Uracil-4-carboxylic acid 50 mg. 2-Thiouracil'4-carhoxylic acid 5-l0 mg.
The recommended dose is 4 or 5 capsules per day.
EXAMPLE 2 Ampuls are prepared each of which contains the following: 30 mg. of the choline salt of Z-thiouracil-4carboxylic acid 200 mg. uracil-4-carboxylic acid, choline salt 250 mg. dl-methionine The ingredients are filled into dry ampuls. In use, one gives 15 ml. sterile, physiological salt solution in the ampul and immediately after dissolution of the active ingredients, the ampul solution is injected (preferably subcutaneoysly).
EXAMPLE 3 Dietetic preparation mg. 2-thiouracil-4-carboxylic acid are homogeneously mixed in 100 g. milk powder. This mild powder is if desired made aromatic. In use, 20 g. of this powder may be dissolved in a cup of hot water and given one to two times daily.
I claim:
1. A pharmaceutical composition which comprises as active ingredients:
a. 2-thiouracil-4-carboxylic acid, or a nontoxic salt or lower alkyl ester thereof; and
b. uracil-4-carboxylic acid, or a nontoxic salt or lower alkyl ester thereof;
wherein the ratio by weight of component (a) to component (b) is about 1:10 and the weight of (a) per dosage unit is from 0.1 mg. to 100 mg.
2. The pharmaceutical composition of claim 1 which also contains methionine.
3. A method of providing a nonspecific activity against virus warts, Molluscum contagiosum, Condylomata acuminata, Herpes simplex, and Herpes zoster in humans which comprises administering thereto a pharmaceutical composition which comprises as active ingredients:
a. 2-thiouracil-4-carboxylic acid, or a nontoxic salt or lower alkyl ester thereof; and b. uracil-4-carboxylic acid, or a nontoxic salt or lower alkyl ester thereof;
in an amount sufficient to provide a dose of about I to 500 mg. per day of component (a), and a dose of about 50 mg. to l gm. per day of component (b), wherein the ratio by weight of component (a) to component (b) is from 1:1 to l: 50.
4. The method of claim 3 wherein the pharmaceutical composition also contains methionine.
5. The method of claim 3 wherein the dose of component (a) is 10 mg. to 50 mg. per day and the dose of component (b) is 100 mg. to 500 mg. per day.

Claims (4)

  1. 2. The pharmaceutical composition of claim 1 which also contains methionine.
  2. 3. A method of providing a nonspecific activity against virus warts, Molluscum contagiosum, Condylomata acuminata, Herpes simplex, and Herpes zoster in humans which comprises administering thereto a pharmaceutical composition which comprises as active ingredients: a. 2-thiouracil-4-carboxylic acid, or a nontoxic salt or lower alkyl ester thereof; and b. uracil-4-carboxylic acid, or a nontoxic salt or lower alkyl ester thereof; in an amount sufficient to provide a dose of about 1 TO 500 mg. per day of component (a), and a dose of about 50 mg. to 1 gm. per day of component (b), wherein the ratio by weight of component (a) to component (b) is from 1:1 to 1: 50.
  3. 4. The method of claim 3 wherein the pharmaceutical composition also contains methionine.
  4. 5. The method of claim 3 wherein the dose of component (a) is 10 mg. to 50 mg. per day and the dose of component (b) is 100 mg. to 500 mg. per day.
US722183A 1967-04-19 1968-04-18 Thiouracil-carboxylic acids for treatment of viruses Expired - Lifetime US3608079A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB08102/67A GB1193192A (en) 1967-04-19 1967-04-19 Pharmaceutical Compositions

Publications (1)

Publication Number Publication Date
US3608079A true US3608079A (en) 1971-09-21

Family

ID=10106685

Family Applications (1)

Application Number Title Priority Date Filing Date
US722183A Expired - Lifetime US3608079A (en) 1967-04-19 1968-04-18 Thiouracil-carboxylic acids for treatment of viruses

Country Status (6)

Country Link
US (1) US3608079A (en)
BE (1) BE713858A (en)
DE (1) DE1767275C3 (en)
FR (1) FR7478M (en)
GB (1) GB1193192A (en)
NL (1) NL140733B (en)

Also Published As

Publication number Publication date
FR7478M (en) 1969-12-01
NL6805514A (en) 1968-10-21
DE1767275C3 (en) 1979-06-21
GB1193192A (en) 1970-05-28
DE1767275B2 (en) 1978-10-26
BE713858A (en) 1968-10-18
DE1767275A1 (en) 1972-04-20
NL140733B (en) 1974-01-15

Similar Documents

Publication Publication Date Title
WO2012140504A1 (en) Therapeutic compounds
US5510381A (en) Method of treatment of mania and bipolar disorder
NZ231718A (en) Pharmaceutical composition comprising a 2',3'-dideoxypurine nucleoside and a purine nucleoside phosphorylase inhibitor
AU629533B2 (en) Improving toxicity profiles in chemotherapy
KR960014991B1 (en) Pharmaceutical compositions containing very low-dosage dioeoxynucleoside
US3608079A (en) Thiouracil-carboxylic acids for treatment of viruses
NL8000140A (en) GLYCERYL PHOSPHORYL DERIVATIVES AND THEIR USE AS A MEDICINAL PRODUCT.
US3852453A (en) Method of enhancing vincamine compositions
US3179562A (en) Treatment of diabetes with alpha, alpha substituted acetic acid derivatives
US4391809A (en) Methods for treating psoriasis
US4720379A (en) Use of dimercaptopropanesulfonic acid and dimercapto-propanesuccinic acid for the preparation of pharmaceutical compositions and a method of treatment
Davies et al. The antituberculous activity of ethyl thiolesters with particular reference to diethyl dithiolisophthalate
NL8101987A (en) THE COMPOUND 4-AMINO-1-BETA-D-RIBOFURANOSYL-1H-IMIDAZO / 4.5-C / -PYRIDINE OR A PHARMACEUTICALLY ACCEPTABLE ACID ADDITION SALT; PHARMACEUTICAL PREPARATION.
US3852433A (en) Uridine-5-monophosphate compositions
JPH04342528A (en) Agent for promotion of alcohol metabolism and acetaldehyde metabolism
US3296074A (en) Methods and compositions for treating psychoses and neuroses
CA1333157C (en) Antihyperlipidemic amines
US5008287A (en) Pharmaceutical compositions having antineoplastic activity
CA1063939A (en) Suppression of thrombocyte aggregation
US3851064A (en) Diphenylsulfides as hypolipidemics
US4329346A (en) Pharmaceutical compositions containing 2,6-bis-(diethanolamino)-4-piperidino-pyrimido[5,4-d]pyrimidine
US3852435A (en) Uridine-5{40 -diphosphate-glucuronic acid compositions
KR910004192A (en) Pharmaceutical composition for treating seizures containing a therapeutically effective amount of propenitoin
UTSUMI et al. Some biological properties of thiaminic acid analogues
ES342394A1 (en) Novel Benzylaminoimidazoline Derivatives, the preparation thereof and Compositions containing the same